Your session is about to expire
← Back to Search
Radiation Therapy
SBRT vs Standard Radiation for Cancer
Phase 2
Recruiting
Led By Anurag K Singh
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Pathologically confirmed malignancy
Clinical or pathologic evidence of metastatic disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks
Awards & highlights
Study Summary
This trial compares single-fraction SBRT to standard radiation therapy in treating metastatic cancer. SBRT uses special equipment to deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Who is the study for?
This trial is for adults with confirmed metastatic cancer causing symptoms or likely to cause symptoms, where radiation could help. They must be able to follow the study plan and complete surveys. Pregnant women, those with brain metastases, recent severe heart issues, active severe infections, or prior radiation at the same site are excluded.Check my eligibility
What is being tested?
The trial compares single-fraction SBRT—a precise high-dose radiation therapy given in one session—to standard palliative radiation therapy over multiple sessions for patients with metastatic cancer. It aims to see which method better relieves symptoms while minimizing harm to healthy tissue.See study design
What are the potential side effects?
Potential side effects include skin reactions at the treatment site, fatigue, nausea, and temporary pain flare-ups. Long-term risks may involve damage to nearby organs or tissues depending on the area treated.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer has been confirmed through lab tests.
Select...
My cancer has spread to other parts of my body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Quality of life
Pain responses
Secondary outcome measures
Overall survival
Other outcome measures
Changes in immune markers
Cognitive function
Frailty Assessment
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Arm II (SBRT)Experimental Treatment3 Interventions
Patients undergo single fraction SBRT.
Group II: Arm I (palliative RT)Experimental Treatment3 Interventions
Patients undergo 1, 3-5, 5-6, or 10 fractions of palliative RT deemed appropriate by the treating physician.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Palliative Radiation Therapy
2015
Completed Phase 1
~20
Stereotactic Body Radiation Therapy
2012
Completed Phase 2
~780
Find a Location
Who is running the clinical trial?
Roswell Park Cancer InstituteLead Sponsor
402 Previous Clinical Trials
29,307 Total Patients Enrolled
Anurag K SinghPrincipal InvestigatorRoswell Park Cancer Institute
5 Previous Clinical Trials
414 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am under the age of 18.I have another cancer besides the one being treated, but it is under control or confirmed to be metastatic.My cancer has been confirmed through lab tests.I am scheduled for surgery to remove or stabilize cancer at the site planned for radiation.I have not had radiation on the same area where more is planned.I do not have severe heart issues, infections needing IV antibiotics, or serious lung problems currently.I am currently pregnant or breastfeeding.My cancer has spread to other parts of my body.I understand this study is experimental and I have signed the consent form.I have brain metastases.My doctor thinks I can't safely join the study.I am unable to give consent for medical procedures.I have cancer symptoms that radiation might relieve.
Research Study Groups:
This trial has the following groups:- Group 1: Arm II (SBRT)
- Group 2: Arm I (palliative RT)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Quality-of-Life Assessment a reliable predictor of patient safety and health outcomes?
"Since this is a phase 2 trial, there is some evidence of safety but not efficacy. Therefore, our team scores Quality-of-Life Assessment as a 2."
Answered by AI
Is there still room for new patients in this clinical trial?
"This research, which was initially published on November 18th 2019, is still recruiting patients according to information found on clinicaltrials.gov. The most recent update was made on May 2nd, 2022."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger